Sun Pharma Canada Inc.

Form 483 issued September 16, 2022 · Brampton, Canada

Inspection
Sep 12 – Sep 16, 2022
Investigator
Marian E. Ramirez
Observations
2
Pages
3
FEI number
3002808384

In short: On September 16, 2022, FDA issued a Form 483 with 2 observations to Sun Pharma Canada Inc. in Brampton, Ontario (FEI 3002808384) after an inspection that ran Sep 12 – Sep 16, 2022. The investigator was Marian E. Ramirez. Most observations concern production; the most-cited regulation is 21 CFR 211.110 (sampling and testing of in-process materials and drug products).

At a glance

2 of 2 observations on this 483 concern production.

Production2

Most cited: 21 CFR 211.110(a) (1×) · 211.100(b) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01

    Written procedures are not established that describe the in-process controls, tests and examinations to be conducted…

  2. 02

    Written production and process control procedures are not followed in the execution of production…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Sun Pharma Canada Inc.?

FDA listed 2 observations on this Form 483, mostly about production. The most-cited regulation is 21 CFR 211.110 (sampling and testing of in-process materials and drug products). The opening words of each observation are shown on this page.

Who inspected Sun Pharma Canada Inc.?

Marian E. Ramirez is named on this Form 483, for the inspection of Sep 12 – Sep 16, 2022. Each investigator has a profile showing what they cite most.

When was Sun Pharma Canada Inc. inspected by FDA?

The inspection ran Sep 12 – Sep 16, 2022, and the Form 483 is dated September 16, 2022.

How do I get the full Form 483 for Sun Pharma Canada Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free